Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free ACB Stock Alerts

Aurora Cannabis (ACB) Competitors

Aurora Cannabis logo
$3.51 +0.09 (+2.63%)
Closing price 06/4/2026 04:00 PM Eastern
Extended Trading
$3.50 0.00 (-0.14%)
As of 06/4/2026 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ACB vs. CGC, CRON, OGI, SNDL, and TLRY

Should you buy Aurora Cannabis stock or one of its competitors? MarketBeat compares Aurora Cannabis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aurora Cannabis include Canopy Growth (CGC), Cronos Group (CRON), Organigram Global (OGI), SNDL (SNDL), and Tilray Brands (TLRY). These companies are all part of the "pharmaceutical products" industry.

How does Aurora Cannabis compare to Canopy Growth?

Aurora Cannabis (NASDAQ:ACB) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Aurora Cannabis has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Canopy Growth
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by company insiders. Comparatively, 0.2% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Canopy Growth had 5 more articles in the media than Aurora Cannabis. MarketBeat recorded 8 mentions for Canopy Growth and 3 mentions for Aurora Cannabis. Canopy Growth's average media sentiment score of 1.09 beat Aurora Cannabis' score of 0.62 indicating that Canopy Growth is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Canopy Growth
5 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Aurora Cannabis has a net margin of -23.46% compared to Canopy Growth's net margin of -94.39%. Aurora Cannabis' return on equity of -0.04% beat Canopy Growth's return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-23.46% -0.04% -0.03%
Canopy Growth -94.39%-46.85%-28.95%

Aurora Cannabis has higher revenue and earnings than Canopy Growth. Aurora Cannabis is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$373.12M0.58$1.63M-$1.08N/A
Canopy Growth$225.65M1.86-$429.86M-$1.30N/A

Summary

Canopy Growth beats Aurora Cannabis on 8 of the 15 factors compared between the two stocks.

How does Aurora Cannabis compare to Cronos Group?

Aurora Cannabis (NASDAQ:ACB) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Aurora Cannabis has higher revenue and earnings than Cronos Group. Aurora Cannabis is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$373.12M0.58$1.63M-$1.08N/A
Cronos Group$146.59M7.15-$9.45M$0.01280.00

Aurora Cannabis has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Cronos Group has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Cronos Group has a consensus target price of $2.30, suggesting a potential downside of 17.86%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts clearly believe Cronos Group is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cronos Group
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Comparatively, 7.8% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cronos Group had 2 more articles in the media than Aurora Cannabis. MarketBeat recorded 5 mentions for Cronos Group and 3 mentions for Aurora Cannabis. Aurora Cannabis' average media sentiment score of 0.62 beat Cronos Group's score of 0.55 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cronos Group
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Cronos Group has a net margin of -1.14% compared to Aurora Cannabis' net margin of -23.46%. Aurora Cannabis' return on equity of -0.04% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-23.46% -0.04% -0.03%
Cronos Group -1.14%-1.26%-1.20%

Summary

Cronos Group beats Aurora Cannabis on 10 of the 16 factors compared between the two stocks.

How does Aurora Cannabis compare to Organigram Global?

Aurora Cannabis (NASDAQ:ACB) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Organigram Global has a net margin of -9.22% compared to Aurora Cannabis' net margin of -23.46%. Aurora Cannabis' return on equity of -0.04% beat Organigram Global's return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-23.46% -0.04% -0.03%
Organigram Global -9.22%-13.41%-9.09%

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 34.6% of Organigram Global shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by company insiders. Comparatively, 0.1% of Organigram Global shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aurora Cannabis has higher revenue and earnings than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$373.12M0.58$1.63M-$1.08N/A
Organigram Global$185.07M0.82-$17.70M-$0.13N/A

Aurora Cannabis has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Organigram Global has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Organigram Global
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Aurora Cannabis had 2 more articles in the media than Organigram Global. MarketBeat recorded 3 mentions for Aurora Cannabis and 1 mentions for Organigram Global. Organigram Global's average media sentiment score of 0.94 beat Aurora Cannabis' score of 0.62 indicating that Organigram Global is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Organigram Global
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Organigram Global beats Aurora Cannabis on 8 of the 15 factors compared between the two stocks.

How does Aurora Cannabis compare to SNDL?

SNDL (NASDAQ:SNDL) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

SNDL has a net margin of -1.19% compared to Aurora Cannabis' net margin of -23.46%. Aurora Cannabis' return on equity of -0.04% beat SNDL's return on equity.

Company Net Margins Return on Equity Return on Assets
SNDL-1.19% -1.02% -0.85%
Aurora Cannabis -23.46%-0.04%-0.03%

SNDL has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Aurora Cannabis has lower revenue, but higher earnings than SNDL. SNDL is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SNDL$677.32M0.54-$11.29M-$0.03N/A
Aurora Cannabis$373.12M0.58$1.63M-$1.08N/A

SNDL currently has a consensus price target of $5.00, suggesting a potential upside of 249.65%. Given SNDL's higher possible upside, research analysts clearly believe SNDL is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SNDL
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aurora Cannabis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

47.6% of Aurora Cannabis shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, SNDL had 2 more articles in the media than Aurora Cannabis. MarketBeat recorded 5 mentions for SNDL and 3 mentions for Aurora Cannabis. SNDL's average media sentiment score of 0.90 beat Aurora Cannabis' score of 0.62 indicating that SNDL is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SNDL
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aurora Cannabis
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

SNDL and Aurora Cannabis tied by winning 7 of the 14 factors compared between the two stocks.

How does Aurora Cannabis compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

9.4% of Tilray Brands shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 0.8% of Tilray Brands shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aurora Cannabis has higher revenue and earnings than Tilray Brands. Aurora Cannabis is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray Brands$210.48M2.87-$2.19B-$13.65N/A
Aurora Cannabis$373.12M0.58$1.63M-$1.08N/A

Tilray Brands currently has a consensus target price of $11.50, suggesting a potential upside of 121.58%. Given Tilray Brands' stronger consensus rating and higher possible upside, research analysts plainly believe Tilray Brands is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray Brands
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25
Aurora Cannabis
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Aurora Cannabis has a net margin of -23.46% compared to Tilray Brands' net margin of -156.51%. Aurora Cannabis' return on equity of -0.04% beat Tilray Brands' return on equity.

Company Net Margins Return on Equity Return on Assets
Tilray Brands-156.51% -3.31% -2.42%
Aurora Cannabis -23.46%-0.04%-0.03%

Tilray Brands has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

In the previous week, Tilray Brands had 7 more articles in the media than Aurora Cannabis. MarketBeat recorded 10 mentions for Tilray Brands and 3 mentions for Aurora Cannabis. Aurora Cannabis' average media sentiment score of 0.62 beat Tilray Brands' score of 0.40 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tilray Brands
4 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aurora Cannabis
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Tilray Brands and Aurora Cannabis tied by winning 8 of the 16 factors compared between the two stocks.

Get Aurora Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACB vs. The Competition

Export
MetricAurora CannabisMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$209.80M$8.07B$6.30B$12.43B
Dividend YieldN/A2.60%2.69%5.33%
P/E Ratio-3.2515.6723.7924.34
Price / Sales0.585.77531.86113.60
Price / Cash5.5917.0041.3955.53
Price / Book0.453.6310.046.72
Net Income$1.63M$224.05M$3.56B$337.03M
7 Day Performance-2.50%1.06%-1.00%-0.13%
1 Month Performance2.03%4.52%2.25%3.76%
1 Year Performance-35.12%3.21%29.12%34.36%

Aurora Cannabis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACB
Aurora Cannabis
0.7853 of 5 stars		$3.51
+2.6%		N/A-37.0%$209.80M$373.12MN/A1,130
CGC
Canopy Growth
2.2174 of 5 stars		$1.08
-0.9%		N/A-20.0%$440.49M$225.65MN/A3,150
CRON
Cronos Group
1.5907 of 5 stars		$2.82
-0.7%		$2.30
-18.4%		+45.1%$1.07B$159.54M282.28450
OGI
Organigram Global
0.6131 of 5 stars		$1.13
-0.9%		N/A-19.4%$160.48M$274.19MN/A1,139
SNDL
SNDL
3.2611 of 5 stars		$1.46
-1.4%		$5.00
+242.5%		+10.9%$380.95M$677.32MN/A2,751

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ACB) was last updated on 6/5/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel